Gilead’s COVID-19 drug is mediocre. It will be a blockbuster anyway.

The company said that by December, it expected to have produced enough drug to treat 2 million patients and that it was studying an inhaled form of the drug that could expand its use to outpatients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2TBvPS1
via IFTTT